USA: Drug Development Solutions Malvern Panalytical Acquires Sensor Specialist Creoptix

Malvern Panalytical, a company providing advanced analysis and services solutions for the pharma drug product development, as well as services and solutions for other industries, has announced its acquisition of Creoptix, a specialist bioanalysis sensor company.

Boston/USA — The acquisition of Creoptix forms a critical part of Malvern Panalytical’s strategy to expand its capabilities in support of drug discovery. Creoptix provides cutting edge tools for molecular interaction analysis. Engineered around their proprietary Grating-Coupled Interferometry (GCI) technology, these tools enable researchers to access high-quality binding affinity and kinetics data across a broader range of samples than traditional SPR-based solutions, accelerating the discovery and development of new drug substances.

Engineered around their proprietary Grating-Coupled Interferometry (GCI) technology, these tools enable researchers to access high-quality binding affinity and kinetics data across a broader range of samples than traditional SPR-based solutions, accelerating the discovery and development of new drug substances.

Integration of Creoptix into the Malvern Panalytical family will start in January 2022 and is planned to be completed within the first half of 2022.

(ID:47935867)